Higgins: LMB 1997-2007, PhD student; Postdoctoral Scientist, Neurobiology; Structural StudiesPlaschka: LMB 2016-2018, Postdoctoral Visitor and Scientist, Structural Studies Congratulations to alumni Matt Higgins and Clemens Plaschka who have both been elected to EMBO Membership. Matt now leads a research group at the Department of Biochemistry, University of Oxford and Clemens is a Senior Group Leader […]
Matt Higgins and Clemens Plaschka elected to EMBO Membership
Architecture of the disease-prone GluA3 receptor unlocks new avenues for drug design
Ingo Greger’s group, in the LMB’s Neurobiology Division, discover that the GluA3 AMPAR adopts a structural organization that substantially diverges from all the other AMPA receptors.
First patient treated for APDS, a rare inherited disorder identified by collaborative Cambridge team including Roger Williams’s group
In 2013, Roger Williams’s group in the LMB’s PNAC Division published findings from a study conducted with researchers at the University of Cambridge, the Babraham Institute and clinicians from Addenbrooke’s Hospital. Together, the team identified a rare genetic mutation which causes a condition now known as Activated PI3K-d Syndrome (APDS), which weakens the immune system […]
HR Advisors Ash Munday, Christina Karikides and Callum Armstrong reflect on earning their CIPD Diplomas
The HR Advisors share their motivations and experience of coordinating pursuing the CIPD qualification studies with their job.
Kelly Nguyen awarded 2025 Lister Prize
Kelly Nguyen, Group Leader in the LMB’s Structural Studies Division, has been announced as one of the 2025 recipients of the prestigious Lister Institute Research Prize.
Sortera Bio has raised £7.5m pre-seed investment from AstraZeneca, BioNTech and CIC
Business Weekly reports that Sortera Bio, an LMB spinout company, has attracted backers for a £7.5m pre-seed round to power AI models for drug discovery. The round was led by Cambridge Innovation Capital (CIC) with participation from AstraZeneca and BioNTech. More…